Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC.PLRX · Entity 7022 | Chief Business Officer | January 23, 2025 | January 27, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PLIANT THERAPEUTICS, INC.
Report date January 23, 2025 · Filed January 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 251,708 |
Reported balance
After 2025-01-23 transaction · row 1
1 source rowRow 1 · 2025-01-23 · Grant · Acquired 40,150 · Balance 251,708 F1: These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.14 · Expires 2035-01-23 | Direct | 80,300 |
Reported balance
After 2025-01-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-01-23 · Grant · Acquired 80,300 · Balance 80,300 F5: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,821 |
Reported balance
Holding disclosure · report date 2025-01-23 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,821 F2: The shares are held by The Sloger Hull Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 13,985 |
Reported balance
Holding disclosure · report date 2025-01-23 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 13,985 F4: The shares are held by a trust for the Reporting Person's minor child ("Child B Trust"). The Reporting Person and his spouse serve as trustees for Child B Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 13,985 |
Reported balance
Holding disclosure · report date 2025-01-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 13,985 F3: The shares are held by a trust for the Reporting Person's minor child ("Child A Trust"). The Reporting Person and his spouse serve as trustees for Child A Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.
F2: The shares are held by The Sloger Hull Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3: The shares are held by a trust for the Reporting Person's minor child ("Child A Trust"). The Reporting Person and his spouse serve as trustees for Child A Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F4: The shares are held by a trust for the Reporting Person's minor child ("Child B Trust"). The Reporting Person and his spouse serve as trustees for Child B Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F5: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2025 Filed Jan 27, 2025 18:07 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 80,300 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001746473-25-000015 · wk-form4_1738019230.xml · derivative · entry 5 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,300 Underlying: Common Stock · 80,300 shares Expires 2035-01-23 F5 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 18:07 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock | 40,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001746473-25-000015 · wk-form4_1738019230.xml · nonDerivative · entry 1 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,708 F1 · shares: These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 17, 2025 Filed Jan 22, 2025 18:02 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 15,936 | $11.20 | $178,500.73 |
DisclosureSEC source: 0001746473-25-000004 · wk-form4_1737586946.xml · nonDerivative · entry 1 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,558 F1 · price: Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $11.03 to $11.695, inclusive, on January 17, 2025 and January 21, 2025 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| July 10, 2024 Filed Jul 12, 2024 18:41 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 9,900 | $11.56 | $114,444.00 |
DisclosureSEC source: 0001746473-24-000127 · wk-form4_1720824069.xml · nonDerivative · entry 1 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 227,494 F1 · price: Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $10.785 to $12.58, inclusive, between July 10, 2024 and July 11, 2024 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 16:58 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock | 19,337 | $0.00 | $0.00 |
DisclosureSEC source: 0001746473-24-000117 · wk-form4_1720731516.xml · nonDerivative · entry 1 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,394 F1 · shares: On July 28, 2022, the Reporting Person was granted 70,312 performance-vested stock units, the vesting of which were subject to the achievement of various pre-established performance criteria. On July 9, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index, resulting in the vesting of 19,337 shares. F2 · balance_after: Includes 1,488 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program. Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 16:57 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 63,000 | $0.00 Strike: $17.44 | $0.00 |
DisclosureSEC source: 0001746473-24-000016 · wk-form4_1706133455.xml · derivative · entry 5 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 63,000 shares Expires 2034-01-23 F5 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 16:57 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock | 31,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001746473-24-000016 · wk-form4_1706133455.xml · nonDerivative · entry 1 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,569 F1 · shares: These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 17:19 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 9,786 | $17.23 | $168,612.78 |
DisclosureSEC source: 0001746473-24-000004 · wk-form4_1705702751.xml · nonDerivative · entry 1 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,069 F1 · price: Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $16.33 to $17.90, inclusive, between January 17, 2024 and January 18, 2024 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 20:50 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionCommon Stock (Right to Buy) · Derivative | 8,791 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001209191-23-044892 · doc4.xml · derivative · entry 10 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,367 Underlying: Common Stock · 8,791 shares Expires 2028-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: On January 24, 2019, the Reporting Person was granted stock options, the vesting of which was subject to the achievement of pre-established performance criteria which were achieved, and all of which were subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 20:50 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 20,050 | $20.01 | $401,200.50 |
DisclosureSEC source: 0001209191-23-044892 · doc4.xml · nonDerivative · entry 5 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,855 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 3, 2023. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.08, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 20:50 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionCommon Stock | 8,791 | $2.08 | $18,285.28 |
DisclosureSEC source: 0001209191-23-044892 · doc4.xml · nonDerivative · entry 4 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 214,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 20:50 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionCommon Stock (Right to Buy) · Derivative | 1,800 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001209191-23-044892 · doc4.xml · derivative · entry 9 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,158 Underlying: Common Stock · 1,800 shares Expires 2028-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: On January 24, 2019, the Reporting Person was granted stock options, the vesting of which was subject to the achievement of pre-established performance criteria which were achieved, and all of which were subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 20:50 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 1,800 | $20.00 | $36,000.00 |
DisclosureSEC source: 0001209191-23-044892 · doc4.xml · nonDerivative · entry 3 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,114 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 3, 2023. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.08, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 20:50 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionCommon Stock | 1,800 | $2.08 | $3,744.00 |
DisclosureSEC source: 0001209191-23-044892 · doc4.xml · nonDerivative · entry 2 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 207,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 20:50 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 13,069 | $20.00 | $261,380.00 |
DisclosureSEC source: 0001209191-23-044892 · doc4.xml · nonDerivative · entry 1 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,114 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 3, 2023. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 20:26 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 17,937 | $18.01 | $323,029.23 |
DisclosureSEC source: 0001209191-23-042829 · doc4.xml · nonDerivative · entry 1 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 219,183 F1 · price: Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $17.63 to $18.47, inclusive, between July 17, 2023 and July 19, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 19:19 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock | 35,156 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-042658 · doc4.xml · nonDerivative · entry 1 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,120 F1 · shares: On July 28, 2022, the Reporting Person was granted 70,312 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On July 14, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 35,156 shares. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 18:51 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 9,036 | $26.52 | $239,642.85 |
DisclosureSEC source: 0001209191-23-022369 · doc4.xml · nonDerivative · entry 1 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201,964 F1 · price: Represents a nondiscretionary sale by the plan established on behalf of the Reporting Person on July 28, 2022 in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $25.88 to $27.235, inclusive, on March 30, 2023 and March 31, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 17:59 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock | 17,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021919 · doc4.xml · nonDerivative · entry 1 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,000 F1 · shares: On July 28, 2022, the Reporting Person was granted 70,313 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On March 29,2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 17,578 shares. F2 · balance_after: Includes 1,231 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 19:15 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (right to buy) · Derivative | 76,200 | $0.00 Strike: $34.65 | $0.00 |
DisclosureSEC source: 0001140361-23-003180 · form4.xml · derivative · entry 5 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,200 Underlying: Common Stock · 76,200 shares Expires 2033-01-24 F5 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 19:15 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock | 54,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-003180 · form4.xml · nonDerivative · entry 1 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,191 F1 · shares: These are restricted stock units that vest in three equal annual installments beginning January 16, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| December 20, 2022 Filed Dec 21, 2022 21:32 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 8,748 | $19.10 | $167,107.80 |
DisclosureSEC source: 0001140361-22-046567 · form4.xml · nonDerivative · entry 2 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,191 F3 · price: The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker at prices ranging from $18.4049 to $19.64, inclusive, on December 20, 2022 and December 21, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:32 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock | 17,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-046567 · form4.xml · nonDerivative · entry 1 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,939 F1 · shares: On July 28, 2022, the Reporting Person was granted 70,313 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On December 19, 2022, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 17,578 shares. F2 · balance_after: Includes 4,115 shares of Common Stock acquired by the Reporting Person pursuant to an employee stock purchase program. Read SEC document |
| January 26, 2022 Filed Feb 2, 2022 20:14 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (right to buy) · Derivative | 112,500 | $0.00 Strike: $11.86 | $0.00 |
DisclosureSEC source: 0001567619-22-002399 · doc1.xml · derivative · entry 1 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2032-01-25 F1 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| May 26, 2021 Filed May 28, 2021 19:58 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionStock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001209191-21-036690 · doc4.xml · derivative · entry 5 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,979 Underlying: Common Stock · 4,500 shares Expires 2029-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| May 26, 2021 Filed May 28, 2021 19:58 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionCommon Stock | 4,500 | $2.08 | $9,360.00 |
DisclosureSEC source: 0001209191-21-036690 · doc4.xml · nonDerivative · entry 1 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2021 Filed Jan 26, 2021 20:00 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (right to buy) · Derivative | 62,250 | $0.00 Strike: $26.50 | $0.00 |
DisclosureSEC source: 0000899243-21-003380 · doc4.xml · derivative · entry 1 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,250 Underlying: Common Stock · 62,250 shares Expires 2031-01-22 F1 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 20:00 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionStock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-000219 · doc4.xml · derivative · entry 5 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,479 Underlying: Common Stock · 3,500 shares Expires 2029-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 20:00 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionCommon Stock | 3,500 | $2.08 | $7,280.00 |
DisclosureSEC source: 0000899243-21-000219 · doc4.xml · nonDerivative · entry 1 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,746 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 21:24 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | ConversionSeries C Preferred Stock · Derivative | 27,322 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015881 · doc4.xml · derivative · entry 8 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,821 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date. F2 · derivative.exercise_date: The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date. F2 · derivative.expiration_date: The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date. F5 · ownership.nature: Shares held by The Sloger Hull Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 21:24 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | ConversionSeries B Preferred Stock · Derivative | 36,319 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015881 · doc4.xml · derivative · entry 7 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,079 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 21:24 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | ConversionCommon Stock | 3,821 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-015881 · doc4.xml · nonDerivative · entry 2 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date. F5 · ownership.nature: Shares held by The Sloger Hull Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 21:24 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | ConversionCommon Stock | 5,079 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-015881 · doc4.xml · nonDerivative · entry 1 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. Read SEC document |
| March 31, 2020 Filed Jun 9, 2020 21:24 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (right to buy) · Derivative | 70,352 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0000899243-20-015881 · doc4.xml · derivative · entry 6 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,352 Underlying: Common Stock · 70,352 shares Expires 2030-03-30 F3 · derivative.exercise_price: On May 22, 2020, the Issuer completed a one-for-7.15 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F3 · shares: On May 22, 2020, the Issuer completed a one-for-7.15 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F4 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 31, 2020 (or if there is no corresponding day in any such month, on the last day of such month), subject to the Reporting Person's continuous service to the Issuer on each such date. F3 · derivative.underlying_shares: On May 22, 2020, the Issuer completed a one-for-7.15 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F3 · balance_after: On May 22, 2020, the Issuer completed a one-for-7.15 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. Read SEC document |
| February 28, 2020 Filed Jun 9, 2020 21:24 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantSeries C Preferred Stock · Derivative | 27,322 | $13.08 | $357,494.71 |
DisclosureSEC source: 0000899243-20-015881 · doc4.xml · derivative · entry 5 Hull Hans · CIK 0001614876 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 27,322 Underlying: Common Stock · 3,821 shares Expires not disclosed F2 · derivative.exercise_price: The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date. F2 · price: The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date. F3 · price: On May 22, 2020, the Issuer completed a one-for-7.15 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F2 · derivative.exercise_date: The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date. F2 · derivative.expiration_date: The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date. F5 · ownership.nature: Shares held by The Sloger Hull Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.